TRSSF - Jaguar Health rises on Street high target U.S. cannabis stocks favored at Jefferies - in today's analyst action

naphtalina/iStock via Getty Images Jaguar Health rises on Street high target from Cantor Jaguar Health (JAGX) has risen ~15.4% in early trading after Cantor Fitzgerald began the coverage with an overweight rating. The Street-high target of $5.00 per share implies a premium of ~235.6% to the last close. The analyst Louise Chen notes that the potential of the company’s antidiarrheal medication Mytesi (crofelemer) is underappreciated. Chen expects Jaguar Health shares to rise thanks to upward revisions to earnings estimates and with the support of several upcoming milestones including, the topline data for Mytesi from a Phase 2 trial in cancer therapy-related diarrhea. In Q1 2021, Mytesi sales rose to $1.2M for Jaguar Health, indicating a ~33.3% YoY growth. ChemoCentryx upgraded at Stifel with positive views on extension to PDUFA date ChemoCentryx (CCXI) has added ~2.1% in the pre-market after Stifel upgraded the stock from hold to buy with the price target raised to $31.00 from

For further details see:

Jaguar Health rises on Street high target, U.S. cannabis stocks favored at Jefferies – in today's analyst action